K Pharma

K-Pharma is a venture company incubated by the Keio University School of Medicine. Relying on induced pluripotent stem cell (iPS) technology, the company focuses on advancing two major businesses: one is regenerative medical treatment for conditions such as spinal cord injuries and cerebral infarctions; the other is drug discovery using disease-specific iPS cells. The company is committed to eliminating unmet medical needs worldwide.